文献速递肿瘤 PET/CT放射性药物与辐射防护

长半衰期89Zr标记放射性示踪剂可在PET/CT室内引导经皮活检而无需重新注射示踪剂

Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.
PubMed 文献 · J Nucl Med · 2017-08-17

研究评估了在PET/CT室内使用89Zr标记放射性示踪剂、不重新注射即完成经皮活检的可行性。2013至2016年共12例疑似转移性前列腺癌或乳腺癌患者接受14次活检,平均注射后6.2天操作,无并发症,病理均阳性,初始影像与活检结果一致。作者结论认为该方法安全有效且无需重新注射示踪剂。

要点

  • 12例患者共14次活检,使用89Zr标记示踪剂,平均剂量180 MBq,未重新注射。
  • 活检在注射后平均6.2天于PET/CT室内完成,所有活检均无并发症。
  • 病理检查所有样本均为恶性,初始诊断影像与活检结果一致。

核心结论

  • 作者结论认为,使用89Zr标记放射性示踪剂的PET/CT引导活检无需重新注射示踪剂,是安全有效的。

研究设计与样本

  • 2013至2016年纳入12例患者(7男5女,平均年龄61岁,范围40-75岁),疑似转移性前列腺癌或乳腺癌,共接受14次经皮活检。
  • 活检在诊断性PET/CT后于PET/CT室内进行,使用89Zr标记放射性示踪剂靶向前列腺特异性膜抗原(n=7)或人表皮生长因子受体2(n=5),不重新注射示踪剂。
  • 示踪剂平均剂量180 MBq(范围126-189 MBq)。

主要发现

  • 所有活检均无并发症,活检在注射示踪剂后平均6.2天(范围0-13天)进行。
  • 活检部位为骨(n=7)、胸膜(n=3)、淋巴结(n=2)和肝脏(n=2)。
  • 病理检查所有活检样本均为恶性,初始诊断影像结果与活检结果一致。
  • CT操作导致的额外辐射(平均剂量长度乘积)为1,581 mGy/cm(范围379-2,686 mGy/cm)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rationale for this study was to evaluate the feasibility of within-suite 89Zr-labeled radiotracer PET/CT-guided biopsy performed without reinjection. Methods: From 2013 to 2016, 12 patients (7 men, 5 women; mean age, 61 y; range, 40-75 y) with metastatic prostate or breast carcinoma suspected either on imaging or because of biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using 89Zr-labeled radiotracers (mean dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific membrane antigen (n = 7) or human epidermal growth factor receptor 2 (n = 5). Biopsy was performed within a PET/CT suite without radiotracer reinjection. Results: There were no complications in any biopsies, which were performed a mean of 6.2 d (range, 0-13 d) after injection of the radiotracer. The biopsy sites were bone (n = 7), pleura (n = 3), lymph nodes (n = 2), and liver (n = 2). On pathologic examination of the biopsy samples, all were positive for malignancy. The initial diagnostic imaging findings were concordant with the biopsy results. The additional radiation (mean dose-length product) due to the CT procedures was 1,581 mGy/cm (range, 379-2,686 mGy/cm). Conclusion: PET/CT-guided biopsy using 89Zr-labeled radiotracers is safe and effective without tracer reinjection.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cornelis FH, Durack JC, Pandit-Taskar N, et al. Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. J Nucl Med. 2017. PMID: 28818992. doi:10.2967/jnumed.117.194480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。